By Rachael Robertson, Enterprise & Investigative Writer
November 9, 2026
For decades, the tetracycline class of antibiotics, including the widely used drug doxycycline, has carried a "cautionary" label for use during pregnancy. Primarily, concerns have centered on the drug’s calcium-chelating properties, which are known to cause tooth discoloration and potential skeletal development issues in a developing fetus. However, a significant new study published in the Annals of Internal Medicine suggests that the risks associated with early exposure to the medication may extend far beyond developmental side effects, pointing to a statistically significant increase in the risk of pregnancy loss.
As clinicians and patients navigate the complexities of treating common infections in women of reproductive age, this new data provides a sobering look at the need for careful risk-benefit analysis when selecting antimicrobial therapies.
The Core Findings: A Significant Statistical Correlation
The retrospective cohort study, led by Almut Winterstein, PharmD, PhD, of the University of Florida in Gainesville, provides some of the most robust data to date regarding the safety profile of doxycycline during the first trimester of pregnancy. By analyzing extensive claims data from both commercially insured (MarketScan) and publicly insured (Medicaid) populations, the research team identified a clear, consistent trend: women exposed to doxycycline in the earliest stages of pregnancy faced a higher likelihood of pregnancy loss compared to those treated with alternative antibiotics.
For women suffering from respiratory tract infections, the results were particularly stark. When compared to amoxicillin—a common, first-line antibiotic—doxycycline use was linked to a significantly higher adjusted risk ratio (aRR) of pregnancy loss. In the Medicaid cohort, the aRR was 1.40 (95% CI 1.28-1.53), while in the privately insured MarketScan cohort, the aRR reached 1.54 (95% CI 1.41-1.68).
The findings remained consistent when doxycycline was compared to macrolide antibiotics, another frequent alternative for respiratory infections. In these comparisons, the risk of pregnancy loss remained elevated, with an aRR of 1.39 in the MarketScan group and 1.36 in the Medicaid group.
Chronology of Research and Methodology
The investigation into these outcomes was a multi-year undertaking, drawing from vast repositories of medical data to ensure statistical power and accuracy. The researchers analyzed data from the Merative MarketScan database, spanning 2005 to 2021, and Medicaid records from 1999 to 2019.
The study design utilized an active-comparator approach, focusing on 218,234 participants. To isolate the effects of the drug, the researchers tracked patients who received either doxycycline or a comparator antibiotic between the moment of conception and the end of the first trimester, roughly defined as the first 76 days of pregnancy.
Inclusion and Exclusion Criteria
To ensure the integrity of the data, the research team established rigorous criteria:
- Age range: Patients aged 12 to 55 were included.
- Continuous coverage: Participants required continuous enrollment 90 days before estimated conception through 30 days after the end of pregnancy.
- Exclusions: To prevent bias, researchers excluded pregnancies with known chromosomal anomalies, multiple gestations, or exposure to other known teratogenic substances. Patients with cancer diagnoses were also removed from the study group to ensure the results reflected the effects of the antibiotic rather than underlying chronic disease complications.
The primary outcome measured was pregnancy loss, defined as either a miscarriage or a stillbirth occurring at 20 weeks of gestation or later.
Supporting Data: The Case of Acne Treatment
While respiratory infections were the primary focus, the study also examined the use of doxycycline for dermatological conditions, specifically acne. This is a critical area of concern, as acne is a chronic condition that often requires long-term antibiotic therapy, frequently in younger women of childbearing age who may not yet be aware they are pregnant.
The results here were nuanced but significant. Among privately insured patients, those prescribed doxycycline for acne faced a 49% higher risk of pregnancy loss compared to those using topical clindamycin (aRR 1.49, 95% CI 1.26-1.76). Interestingly, this association did not reach statistical significance in the Medicaid population (aRR 1.03, 95% CI 0.80-1.33). Researchers noted that the Medicaid population skewed younger, suggesting that external socioeconomic factors or variations in baseline health status might contribute to these disparities, warranting further investigation into how different insurance populations respond to identical treatments.
Official Responses and Expert Perspective
The medical community has reacted with cautious interest to the findings. Dr. Janna Morrison of Adelaide University, who was not involved in the research, highlighted the study’s importance in a statement to the Science Media Centre.
"The results are important because they provide the evidence required by clinicians to decide which antibiotic to prescribe to women of reproductive age or in early pregnancy," Dr. Morrison noted. However, she also offered a balanced perspective, acknowledging that while the findings are statistically robust, they represent only one piece of the puzzle. She emphasized that the study did not examine the long-term effects on the fetus—such as developmental milestones or subtle congenital health issues—which remain a critical concern for obstetricians.
The authors of the study themselves have been measured in their conclusions. "Our findings suggest that clinicians, together with their patients, might want to weigh the benefits against the potential risk for pregnancy loss when considering doxycycline for reproductive-aged women," the team wrote.
Clinical Implications: Moving Toward Safer Prescribing
The implications of this study for daily clinical practice are profound. For years, doxycycline has been a "go-to" medication for a wide variety of bacterial infections. Its effectiveness and broad-spectrum nature made it an easy choice for providers. However, this study serves as a necessary wake-up call regarding the potential, previously under-recognized, reproductive consequences of the drug.
The Challenge of Unplanned Pregnancy
A significant portion of the risk lies in the timing of prescription. Because many pregnancies are unplanned or discovered weeks after conception, women may be taking doxycycline for acne or a respiratory infection during the most critical window of fetal development. If a patient is of reproductive age, the study suggests that providers should now adopt a "pregnancy-first" mindset:
- Screening: Before prescribing doxycycline, clinicians should screen for the possibility of pregnancy.
- Alternatives: In cases where pregnancy is possible or intended, clinicians should prioritize safer, alternative antibiotics that lack the associated risks of pregnancy loss, provided those alternatives are appropriate for the patient’s specific infection.
- Communication: Transparency is key. Patients should be informed of these risks, allowing for shared decision-making that accounts for both the severity of the infection and the potential risk to the pregnancy.
Looking Ahead
The research team is not stopping here. Dr. Winterstein indicated that follow-up studies are already underway, focusing on the health outcomes of live-born infants exposed to the drug in utero. This will provide a more comprehensive view of the drug’s safety profile, potentially moving beyond the binary outcome of pregnancy loss to a more detailed understanding of fetal health.
Ultimately, while no medical intervention is entirely without risk, this study underscores the necessity of caution. As the medical community continues to refine its understanding of drug-pregnancy interactions, the data suggests that for doxycycline, the threshold for prescription to women of reproductive age should be significantly higher.
By integrating these findings into clinical practice, doctors can better protect the health of both their patients and their patients’ future children, ensuring that the treatment of today does not compromise the promise of tomorrow.
